Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42
Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39
Evercore ISI Group Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $50
Goldman Sachs Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $36
Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY
Len Blavatnik And Access Industries Report 10.4% Stake In Hemab Therapeutics As Of May 4, 2026
Hemab Therapeutics IPO Opens For Trade At $27/Share; IPO Priced At $18/Share On 16.75M Shares
Hemab Therapeutics Begins IPO Effort On Positive Trial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
